A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases

NCT05042791 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

362

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Metastatic Breast Cancer

Interventions

COMBINATION_PRODUCT: radiation combined with pyrotinib and capecitabine

Sponsor

Jiangxi Provincial Cancer Hospital